Hamdan, Abel
Sharma, Sumit
Baynes, Kimberly
Hajj Ali, Rula A.
Lowder, Careen Y.
Srivastava, Sunil K.
Article History
Received: 23 January 2024
Accepted: 4 May 2024
First Online: 30 July 2024
Declarations
:
: Complying with the tenets of the Declaration of Helsinki, a retrospective case series was created and approved by the Institutional Review Board of the Cleveland Clinic Foundation under reference / ID # 13–788.
: Not applicable
: There are no competing interests for any author.
: Rare side effects associated with anti-TNF medications include rare neurological complications and demyelinating disease. Immunosuppressive management and long term outcomes of uveitis patients who develop these complications are not clear.
: Patients may have no evidence of higher neurological risk prior to starting an anti-TNF treatment. Discontinuation of an anti-TNF agent and subsequent control of disease is possible with alternative immunosuppressive treatments.
: Despite the absence of any prior risk factors, practitioners should be cautious of new neurological disease in patients who present with neurological symptoms while on an anti-TNF medication. Patients who present with adverse neurological reactions while on anti-TNF agents can be rescued while minimizing negative sequelae when given appropriate magnetic resonance imaging (MRI)/steroid management and alternative long-term medications.
: Patients may have no evidence of higher neurological risk prior to starting an anti-TNF treatment. Discontinuation of an anti-TNF agent and subsequent control of disease is possible with alternative immunosuppressive treatments.